Monte Rosa Therapeutics, Inc. Restricted Cash and Cash Equivalents
Monte Rosa Therapeutics, Inc. (GLUE) had Restricted Cash and Cash Equivalents of $326.10 million as of 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2025-05-08
- 2025-03-31: Restricted Cash and Cash Equivalents $326.10M.
- 2024-12-31: Restricted Cash and Cash Equivalents $372.10M.
- 2024-09-30: Restricted Cash and Cash Equivalents $242.20M.
- 2024-06-30: Restricted Cash and Cash Equivalents $262.20M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2025-03-31 | $326.10M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $372.10M 10-K · filed 2025-03-20 |
| 2024-09-30 | $242.20M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $262.20M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $192.90M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $232.40M 10-K · filed 2024-03-14 |
| 2023-09-30 | $178.50M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $203.10M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $231.70M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $262.80M 10-K · filed 2023-03-16 |
| 2022-09-30 | $272.10M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $294.10M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $317.20M 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |